DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a vast dataset of hair samples collected and analyzed in 2023.
As pioneers in the field of hair testing, Psychemedics collected hundreds of thousands of hair samples from individuals across diverse industries and regions. Leveraging advanced analytical techniques, the Psychemedics team meticulously analyzed these samples to detect a wide range of drugs and metabolites, forming the foundation of the insights.
The 2024 Insights Report serves as a testament to the efficacy and advantages of hair testing as the premier method for employment drug screening. It highlights key findings and trends, including:
“In our inaugural report, Psychemedics is proud to unveil a comprehensive analysis of workplace drug use trends,” stated Brian Hullinger, President and Chief Executive Officer at Psychemedics. “As an industry leader in hair testing, Psychemedics remains committed to advancing the field of drug testing and providing innovative solutions to create safer and more productive workplaces.”
The 2024 Psychemedics Insights Report serves as a vital resource for employers, policymakers, and stakeholders seeking to understand and address the complex challenges posed by drug use in the workforce. To access the full report and learn more about Psychemedics’ pioneering hair testing solutions, visit https://www.psychemedics.com/wp-content/uploads/2024/06/PMD-2024-Workforce-Insights-Report.pdf.
For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit https://www.psychemedics.com.
About Psychemedics
Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.
Investor Relations:
Phone: 978-206-8220
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.67 |
Daily Volume: | 0 |
Market Cap: | US$15.730M |
November 12, 2024 August 29, 2024 August 13, 2024 March 28, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load